Rankings
▼
Calendar
▼
NGEN Q1 2018 Earnings Report — NervGen Pharma Corp. Common stock Revenue & Financial Results | Market Cap Arena
NervGen Pharma Corp. Common stock
NGEN
Q1 2018 Earnings
Reported March 30, 2018
Quarter Comparison
Revenue
Operating Income
EPS (Diluted)
Metric
Q1 2018
Q4 2017
Q1 2017
QoQ Change
YoY Change
Revenue
$0
$0
—
—
—
Op. Income
-$8.2K
-$5.1K
—
-61.8%
—
EPS (Diluted)
$0.00
$0.00
—
Infinity%
—
marketcaparena.com
Income Statement
Item
Amount
REVENUE
$0
Cost of Revenue
-$414
GROSS PROFIT
$414
R&D Expenses
-$12.0K
Selling & Marketing
$0
General & Administrative
$0
SG&A Expenses
$8.2K
Other Expenses
$12.0K
Operating Expenses
$8.2K
Cost & Expenses
$8.2K
OPERATING INCOME
-$8.2K
Interest Income
$0
Interest Expense
$0
Other Income/Expenses
$0
INCOME BEFORE TAX
-$8.2K
Income Tax Expense
$0
Net Income from Continuing Ops
-$8.2K
Net Income from Discontinued Ops
$0
Other Adjustments
$0
NET INCOME
-$8.2K
Net Income Deductions
$0
BOTTOM LINE NET INCOME
$15.4K
D&A
$0
EBIT
-$8.2K
EBITDA
-$8.2K
EPS
$0
EPS Diluted
$0
marketcaparena.com
← FY 2018
NGEN Overview
Q2 2018 →